SCHEDULE: S.H.N. Financial Investments Amends Applied DNA Sciences Stake

S.H.N. Financial Investments Ltd. has amended its beneficial ownership in Applied DNA Sciences Inc., now holding 3.4% of the common stock through warrants.

Summary

• S.H.N. Financial Investments Ltd. filed an amendment to its Schedule 13G for Applied DNA Sciences Inc. on November 14, 2025.
• The reporting person beneficially owns 155,586 securities, which represents 3.4% of the common stock.
• This beneficial ownership is comprised of 152,669 Series A Warrants and 2,917 Series C Warrants, each convertible into common stock.
• The previous Schedule 13G, filed on June 7, 2024, reported ownership of 1,013,807 common shares purchased on May 28, 2024.
• The 3.4% ownership percentage is calculated based on 4,354,782 common shares of Applied DNA Sciences Inc. outstanding as of October 31, 2025.
• Nir Shamir, the Chief Executive Officer of S.H.N. Financial Investments Ltd., may be deemed to beneficially own these securities but disclaims beneficial ownership for all other purposes.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant reduction in the reported beneficial ownership amount and the shift from direct common shares to warrants, which may imply a less bullish stance from the reporting person.

Positives

• S.H.N. Financial Investments Ltd. maintains an investment in Applied DNA Sciences Inc., indicating continued interest, albeit in a different form.

Negatives

• The amendment reflects a significant reduction in the reported beneficial ownership amount, from 1,013,807 common shares to 155,586 warrants.
• The shift from direct common share ownership to warrants may be perceived as a less direct or less confident equity position.

Risks

• The beneficial ownership is now primarily in warrants, which carry different risk profiles than common stock, including potential expiration or dilution upon exercise.

Future Outlook

NA

Management Comments

• Nir Shamir, Chief Executive Officer of S.H.N. Financial Investments Ltd., may be deemed to beneficially own the securities described herein, but disclaims beneficial ownership for all other purposes.

Industry Context

This filing details a change in an institutional investor's stake in Applied DNA Sciences, a company operating in a sector that likely involves biotechnology or security solutions. It provides insight into a specific investor's evolving position rather than broad industry trends.

Stakeholder Impact

• Shareholders: The reduction in direct common share ownership by an institutional investor and the shift to warrants could be perceived negatively, potentially impacting investor confidence and market sentiment.

Key Dates

Recommendation

S.H.N. Financial Investments Ltd. has significantly altered its reported beneficial ownership in Applied DNA Sciences Inc., moving from over 1 million common shares to 155,586 warrants. This change, particularly the reduction in direct equity exposure and the shift to a different security type, suggests a re-evaluation of the investor's position. While not a definitive sell signal, it does not present a strong positive catalyst. A 'hold' recommendation is appropriate to monitor the company's performance and any further actions by this or other institutional investors.

Keywords

Applied DNA Sciences, S.H.N. Financial Investments, Schedule 13G, beneficial ownership, common stock, warrants, ADNAS, equity stake, institutional ownership